Market Overview

Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency

Related ARWR
Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT
Arrowhead Offers Data on ARC-520, ARC-AAT at AASLD The Liver Meeting

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application U.S. 13/032,029 entitled, “Compositions for Targeted Delivery of siRNA.” The patent broadly covers compositions, methods, and uses for a new formulation of Arrowhead's Dynamic Polyconjugate (DPC) siRNA delivery platform, where attachment of siRNA and delivery vehicle is not required to produce high-level, efficient knockdown of target genes. The new IP expands the DPC platform and is used in Arrowhead's ARC-520 candidate in development for chronic hepatitis B virus (HBV) infection.

Posted-In: News Legal

 

Related Articles (ARWR)

Around the Web, We're Loving...

Get Benzinga's Newsletters